BeiGene Successfully Hosts the 4th BeiGene Summit of Solid Tumor (BEST)
On October 22, 2022, the 4th BeiGene Summit of Solid Tumor (BEST) was successfully held. This summit focused on“Hundred Aspirations, Shared Resilience; Harnessing Trends, Symbiotic Growth”themed around, focusing onSolid TumorsHotspots in the therapeutic landscape: A premier dialogue on global R&D trends and the latest clinical diagnosis and treatment advancements in innovative therapies for solid tumors, uniting stakeholders from industry, academia, research, and healthcare to jointly steer the future of innovation in solid tumor treatment.
The entire summit was held online, bringing together numerous leading experts and scholars in the field of solid tumors from both China and abroad to jointly participate in this academic event.
As a high-profile annual academic summit held for four consecutive years, the BeiGene Solid Tumor Summit brings together extensive expert insights and discussions: Shandong Cancer HospitalYu JinmingAcademician, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyMartinAcademician, Zhongshan Hospital Affiliated to Fudan UniversityFan JiaAcademician, Chinese PLA General HospitalZhang XuAcademician, Chinese PLA General HospitalJiang ZefeiProfessor, Peking University International HospitalLiang JunProfessor, Peking University Cancer HospitalShen LinProfessor, Guangdong Provincial People's HospitalWu YilongProfessor, Sun Yat-sen University Cancer CenterXu RuihuaProfessor, and President, Chief Operating Officer, and General Manager of China Region at BeiGeneWu XiaobinPh.D., Senior Vice President and Head of Global R&D, BeiGeneWang LaiThe Ph.D. delivered a speech or keynote address at the conference, discussing new breakthroughs, developments, and prospects in the global fight against solid tumors.
According to the latest data from the World Health Organization, there were 19.29 million new cancer cases globally in 2020,9.96 million cancer deaths[1], the major cancer types with high global incidence are all solid tumors. With the rapid development of clinical research and new drug development for solid tumors worldwide, an increasing number of innovative oncology drugs are coming into patients’ view,Bringing New Hope to Patients with Solid Tumors Worldwide。
Yu JinmingAcademician stated: As one of the major diseases threatening the health of Chinese residents, cancerOncologyPrecision Prevention and Control SystemThe establishment of is key to improving cancer prevention and treatment. More and more innovative drugs are emerging, continuously driving clinical diagnosis and treatment practices in China, and benefiting more cancer patientsAccessible, Affordable, and DurableThese high-quality immunotherapy drugs. “We are delighted to see innovative biopharmaceutical companies, represented by BeiGene, working closely with domestic clinical experts to truly achieve a win-win outcome, jointly overcome challenges, elevate academic standards, and advance the cause of cancer prevention and treatment.”
Recurrent ovarian cancer, cervical cancer, and endometrial cancer are the three major malignancies that seriously threaten women's health.Gynecologic Oncology[2][[3][4], is a field of solid tumors that requires high attention.MartinAcademician stated: The "Outline of the 'Healthy China 2030' Plan" proposes to increase the overall 5-year cancer survival rate by 15% by 2030, which is a significant and challenging task for us. Currently, tumor treatment has evolved from past radiotherapy, chemotherapy, and surgery into the era of precision medicine. "BeiGene has made substantial contributions in solid tumors, particularly gynecologic oncology. PARP inhibitor pamiparib and PD-1 inhibitor tislelizumab, among others, have significantly improved patient prognosis. We hopeNational Government, Society, Enterprises, and Medical ProfessionalsJoin forces toGynecologic Oncology, major diseases such as solid tumors have achieved excellent therapeutic outcomes through our efforts, truly benefiting the broad masses of the people.”
In China,Liver Canceris one of the leading causes of cancer-related deaths, while primary liver cancer ranks as the fourth most common malignant tumor and the second leading cause of cancer-related mortality in China[5][6][7], with significant unmet medical needs.Academician Fan JiaIt indicates that, in addition to continuously leading innovations in medical diagnostic and therapeutic technologies, the development of new drugs is also a critical component. Innovative concepts and approaches in diagnosis and treatment can truly benefit patients only through high-quality academic exchange. “We are pleased to see that BeiGene, in order to meet the clinical needs of liver cancer patients in China,Deepening R&D efforts and continuously launching innovative treatment solutions, while consistently providing high-quality academic exchange platforms. Today, we gather here to exchange the latest academic advancements, look forward to acquiring the most cutting-edge information through this conference, connect with more like-minded colleagues, and work together to benefit more patients.”
In addition to liver cancer, tumor immunotherapy in previously approved drugswith very limited pharmacological treatment optionsUrologic TumorsBreakthrough progress has also been achieved in China.Zhang XuAcademician stated: Immunotherapy has become the standard of care for urothelial carcinoma and renal cell carcinoma, significantly prolonging patient survival. In recent years, the application of immunotherapy in China has become increasingly widespread, which is inseparable from the rise and efforts of innovative pharmaceutical companies. “The approval of tislelizumab for the indication of urothelial carcinoma has made itThe First PD-1 Monoclonal Antibody Approved for This Indication in China Holds Epoch-Making Significance“It is encouraging to see BeiGene actively expanding its global clinical research footprint, and we look forward to seeing tislelizumab benefit patients worldwide as soon as possible.”
At the meeting, the experts also discussedGastrointestinal Tumors、Bone Metastasis of Tumorheld discussions in areas and on topics such as, and stated: ChinaGastrointestinal TumorsWith over one million new cases diagnosed annually, patients often face significant challenges, including late diagnosis, poor prognosis, and a heavy disease burden. For many years, the field of gastrointestinal oncology has seen few innovative drugs and suboptimal treatment outcomes, leaving a substantial unmet medical need. Addressing this challenge requires greater contributions from innovative enterprises like BeiGene, working in concert with clinical experts to overcome these obstacles.Bone Metastasis of Tumorsa growing challenge faced by patients, whose unique characteristics makeMultidisciplinary Team (MDT) Modelbecome the norm,Enable physicians across different tumor types and specialties to leverage their expertise in the diagnosis and treatment of bone metastases, enabling patients with advanced-stage cancer to prolong survival whileBetter uphold the dignity of life.
In recent years, clinical research and trials in China’s innovative oncology drug industry have witnessed robust growth. Data show that in 2015, the total number of core clinical trials for innovative drugs conducted in China, the United States, Europe, and Japan was 1,091, with China accounting for only 9.3%. By 2021, although the total number had slightly increased to 1,122, China’s share rose significantly to 354 trials, representing 31.6% of the total.[8]. Chinese clinical trials, in terms of both quantity and quality, are beginning to gain prominence on the international stage.
Xu RuihuaAt the conference, the professor stated that BeiGene’s BEST Academic Conference has played a significant role in advancing clinical oncology. “As a clinical oncology society, we have maintained a long-standing and dedicated collaboration with BeiGene, achieving substantial progress across various fields, particularly in solid tumors.”‘Medicine’ and ‘Pharmaceuticals’: A Partnership Elevating China’s Clinical Diagnosis and Treatment to New Heights. Today’s program was rich in content, featuring particularly robust academic exchanges among leading scholars and representatives from various academic fields, fostering mutual inspiration.Strengthen cooperation.”
Wu YilongThe professor stated, “BeiGene has recently achieved a new global breakthrough: in the head-to-head study comparing its zanubrutinib with ibrutinib, it was confirmed that we have the capability to become ‘BEST,’ and we are determined to achieve this status. Today’s conference has attracted many academicians and clinical experts in solid tumors. I believe that such academic exchanges are an ongoing journey without end. Only through such exchanges can we clarify the path forward. By choosing the right path toward the future, we may, like BeiGene, become ‘BEST’!”
Jiang ZefeiThe professor emphasized, “BeiGene is both a nationally rooted, independently operated company and a more globally oriented innovative pharmaceutical enterprise. Conferences like BEST will undoubtedly foster a strong academic atmosphere. It is our hope that such exchanges will help build greater consensus and drive progress in the industry.”
Liang JunThe professor remarked, “We must join forces to advance immunotherapy and combination immuno-oncology regimens for liver cancer, working more closely together to provide patients with the optimal and most cost-effective treatment strategies. Through this BEST Conference, let us unite in our shared aspirations and thrive by harnessing emerging trends!”
Shen LinAt the conference, the professor stated, “This congress covers common cancers in China, cancers with unique incidence patterns in China, and refractory malignancies. The content presented represents gold-standard insights, reflecting the current status and level of cancer research in our country. It showcases researchers’ perspectives and future projections regarding these diseases. More importantly, it highlights BeiGene’s strategic layout across the entire oncology landscape, as well as its significant role in driving and leading cancer research in China, with many areas already at the international forefront. We look forward to continued collaboration with companies like BeiGene to address the shared challenges in global cancer treatment.”
BeiGene inIn terms of product pipeline layout, the company focuses on the oncology field and is currently one of the innovative enterprises with the most extensive coverage in the treatment of solid tumors.Wang LaiDr. stated: Over the past 12 years of its journey, BeiGene has always adhered toPatients First、Science-Basedphilosophy, aiming to lead the transformation of the entire biopharmaceutical industry and develop innovative drugs that are both effective and accessible. In addition to BeiGene’s consistent focus onHematologic MalignanciesandSolid TumorsOutside the field, in recent years, we have begun to enterImmuno-oncologyandImmune Inflammationfield, and we look forward to more and more complex effective drugs entering the clinical stage in the next decade.We look forward to continuing in-depth collaboration with researchers to ensure these drugs benefit patients in China as soon as possible and contribute to global health.“
Wu XiaobinThe doctor stated, “Thanks to the enhanced interaction between innovative enterprises and clinicians, the pace of medical translation has accelerated significantly, allowing the general public and patients to experience the speed, affordability, and high quality of China’s innovative drugs. BeiGene has consistently provided strong support for clinicians in conducting academic discussions and has collaborated with numerous experts to explore innovative treatment regimens through investigator-initiated studies. We are privileged to witness an increasing number of studies led by Chinese scholars gaining prominence on the international stage.”Bringing Chinese Wisdom to the Global Academic Community; at the same time, they will alsoBringing International Cutting-Edge Research Findings Back to China, continue to guide innovative companies in their approach to conducting clinical trials. In the future,Beigene will continue to work hand in hand with clinical experts to explore innovative treatment regimens, contributing Chinese strength to the benefit of patients both in China and worldwide.。”
*The product information contained herein is intended solely for the purpose of scientific exchange and is for reference by healthcare professionals only. For prescribing information, please refer to the package insert approved by the National Medical Products Administration.*
[1] WHO 2020 Report on the Burden of Cancer
[2] Gynecologic Oncology Professional Committee of the China Anti-Cancer Association. Guidelines for the Diagnosis and Treatment of Ovarian Malignancies (2021 Edition) [J]. China Oncology, 2021, 31(6): 490-500.
[3] Gynecologic Oncology Committee of the China Anti-Cancer Association. Guidelines for the Diagnosis and Treatment of Cervical Cancer (2021 Edition) [J]. Chinese Journal of Cancer, 2021, 31(6): 474-489.
[4] Gynecologic Oncology Committee of the China Anti-Cancer Association. Guidelines for the Diagnosis and Treatment of Endometrial Cancer (2021 Edition) [J]. Chinese Journal of Cancer, 2021, 31(6): 501-512.
[5] Zhou M,Wang H, Zeng X, et al. Mortality,morbidity, and risk factors in China and its provinces，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-58.
[6] Chen W, Zheng R, Baade PD,et al.Cancer statistics in China,2015[J]. CA Cancer J Clin, 2016, 66(2):115-32.
[7] https ://gco.iarc.fr/today/data/factsheets/cancers/ll-Liver-fact-sheet.pdf.
[8] PharmaCube's Pharma Go Database